NCT01871376View on ClinicalTrials.gov

Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Polypoidal Choroidal Vasculopathy
Interventions
DRUG

Intravitreal aflibercept injection 2.0mg

Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.

Trial Locations (1)

96701

Retina Consultants of Hawaii, ‘Aiea

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Gregg T. Kokame, MD

OTHER

NCT01871376 - Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation | Biotech Hunter | Biotech Hunter